A Multi-Center, Single-Arm, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined with Atezolizumab in Subjects with Locally Advanced or Metastatic Urothelial Carcinoma who have Progressed Following Platinum-based Chemotherapy